Scientific Sessions 2024  /  Featured Science: Novel Approaches to Managing Lipid Risk  /  Discussant: PALISADE
Logo

American Heart Association

  204
  0

Final ID:

Discussant: PALISADE

  • Shapiro, Michael  ( Wake Forest Univ School of Medicine , Winston Salem , North Carolina , United States )
    • Author Disclosures:
    Michael Shapiro: DO have relevant financial relationships ; Consultant:Amgen:Active (exists now) ; Advisor:Arrowhead:Active (exists now) ; Advisor:Merck:Active (exists now) ; Consultant:Regeneron:Active (exists now) ; Advisor:Ionis:Active (exists now) ; Advisor:Agepha:Past (completed) ; Consultant:Novartis:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Featured Science: Novel Approaches to Managing Lipid Risk

Saturday, 11/16/2024 , 01:30PM - 02:45PM

Featured Science

More abstracts on this topic:
Efficacy and Safety of Lerodalcibep, a Third Generation PCSK9 Inhibitor, in 703 Heterozygous Familial Hypercholesterolemia Subjects in the Open Label Extension Trial

Raal Frederick, Fourie Nyda, Scott Russell, Blom Dirk, Kayikcioglu Meral, Vest Jeff, Kallend David, Stein Evan

Long-term Efficacy of Lerodalcibep in 1,468 Patients at Very High and High Risk for CVD in the 72 week Open-Label Extension Trial

Kereiakes Dean, Fourie Nyda, Scott Russell, Asprusten Emil, Yalim Zafer, Vest Jeff, Kallend David, Stein Evan

More abstracts from these authors:
Opportunities to Implement Cardiometabolic Health Promotion in the Cardiac Cath Lab

Michos Erin, Shapiro Michael

Debate: Should Statins be Started in Young Individuals for Primary Prevention? (Pro)

Shapiro Michael, Bailey Alison

You have to be authorized to contact abstract author. Please, Login
Not Available